Coupling HA Molecules from Various Flu Strains Could Make Vaccines More Effective
Results from a recent study suggest coupling HA molecules from various flu strains could make flu vaccines more effective.
FDA Approves Chikungunya Vaccine
The U.S. Food and Drug Administration (FDA) has approved VIMKUNYA (chikungunya vaccine, recombinant) for injection, the first virus-like particle (VLP) single-dose chikungunya vaccine in the U.S. for persons 12 years of age and older.
HHS Announces 15 Additional Drugs for Price Negotiations
The Centers for Medicare and Medicaid Services (CMS) has announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations.
GSK’s Penmenvy Meningococcal Vaccine Approved by FDA
GSK’s Penmenvy (meningococcal groups A, B, C, W and Y vaccine) has been approved by the U.S. Food and Drug Administration for use in individuals aged 10 through 25 years.
FDA Approves New Medication for Acute Pain
The U.S. Food and Drug Administration has approved Vertex Pharmaceutical’s Journavx (suzetrigine), a new type of prescription pain medication for adults to treat moderate to severe acute pain.
RSV Vaccine Prompts Robust Response in Older Recipients
Findings of a Phase III randomized controlled trial showed Pfizer’s RSV Prefusion F (RSVpreF) vaccine triggered strong immune responses among people aged 60 years and older during its first two seasons.
Grant Allows UCLA to Launch Autoimmunity Center to Find Cures
The National Institutes of Health has awarded a $3.4 million grant to help establish a new Autoimmunity Center of Excellence at the University of California, Los Angeles.
Grant Awarded to Accelerate Pandemic Influenza mRNA Vaccine Development
The U.S. Department of Health andHuman Services will provide approximately $590 million to Moderna to accelerate the development of mRNAbased pandemic influenza vaccines and enhance mRNA platform capabilities
Multiple Myeloma Patients Treated with Teclistamab May Benefit from IVIG Supplementation
Results of a recent study show patients with multiple myeloma undergoing teclistamab therapy may benefit from primary intravenous immune globulin supplementation, which appears to reduce the risk of high-grade infection.
New Biosimilar Autoimmune Disease Treatment Approved by FDA
Celltrion’s Avtozma (tocilizumabanoh), a biosimilar to Actemra (tocilizumab), in both intravenous (IV)and subcutaneous (SC) formulations, has been approved by the U.S. Food and Drug Administration.
